Requip en es it fr

Requip Brand names, Requip Analogs

Requip Brand Names Mixture

  • No information avaliable

Requip Chemical_Formula


Requip RX_link

Requip fda sheet

Requip FDA

Requip msds (material safety sheet)

Requip MSDS

Requip Synthesis Reference

No information avaliable

Requip Molecular Weight

260.375 g/mol

Requip Melting Point

243-250 oC

Requip H2O Solubility

133 mg/mL

Requip State


Requip LogP


Requip Dosage Forms

Tablet (0.25 mg, 0.5 mg, 1 mg, 2 mg, 4 mg or 5 mg)

Requip Indication

For the treatment of the signs and symptoms of idiopathic Parkinson's disease. Also used for the treatment of restless legs syndrome.

Requip Pharmacology

Ropinirole is a nonergot dopamine agonist with high relative in vitro specificity and full intrinsic activity at the D2 subfamily of dopamine receptors, binding with higher affinity to D3 than to D2 or D4 receptor subtypes. The relevance of D3 receptor binding in Parkinson's disease is unknown. The mechanism of ropinirole-induced postural hypotension is presumed to be due to a D2 -mediated blunting of the noradrenergic response to standing and subsequent decrease in peripheral vascular resistance.

Requip Absorption

Absolute bioavailability is 55%, indicating a first pass effect. Food does not affect the extent of absorption.

Requip side effects and Toxicity

Symptoms of overdose include agitation, chest pain, confusion, drowsiness, facial muscle movements, grogginess, increased jerkiness of movement, symptoms of low blood pressure (dizziness, light-headedness)upon standing, nausea, and vomiting.

Requip Patient Information

No information avaliable

Requip Organisms Affected

Humans and other mammals